SCHEMBL26933489

SCHEMBL26933489

CCc1ccc2cnccc2c1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 5/20 0.56
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
CACNA1B Q00975 1/20 0.40
ERN1 O75460 1/20 0.40
RPS6KB1 P23443 2/20 0.38
ROS1 P08922 1/20 0.38
CYP2D6 P10635 3/20 0.38
CYP3A4 P08684 2/20 0.38
KDM4E B2RXH2 2/20 0.38
CYP2C19 P33261 2/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAPKAPK2 P49137 1/20 0.38
PRKCZ Q05513 2/20 0.37
PRKCD Q05655 2/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9883140 0.79 IMPDH2 (0.40) IMPDH2CACNA1BERN1RPS6KB1CYP2D6
SCHEMBL9883128 0.79 IMPDH2 (0.56) IMPDH2CACNA1BERN1RPS6KB1CYP2D6
SCHEMBL26933089 0.76 ERN1 (0.61) IMPDH2CACNA1BERN1RPS6KB1CYP2D6
SCHEMBL26933278 0.76 IMPDH2 (0.61) IMPDH2CACNA1BERN1RPS6KB1CYP2D6
SCHEMBL31629068 0.76 IMPDH2 (0.61) IMPDH2ERN1RPS6KB1CYP2D6CYP3A4
SCHEMBL15201623 0.76 IMPDH2 (0.61) IMPDH2ERN1RPS6KB1CYP2D6CYP3A4
SCHEMBL2627867 0.74 LMNA (0.53) RPS6KB1ROS1CYP2D6CYP3A4KDM4E
SCHEMBL25987928 0.73 IMPDH2 (0.50) IMPDH2CYP2D6CYP3A4KDM4ECYP2C19
SCHEMBL18910419 0.73 KDM4C (0.39) IMPDH2ERN1CYP2D6CYP3A4KDM4E
SCHEMBL30640504 0.73 GABRA1 (0.52) GABRA1GABRB2ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof BAUSCH + LOMB IRELAND LIMITED (IE) 2025-10-07 US disclosed
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2024-09-19 US disclosed
EP-4313951-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-02-07 EP disclosed
US-11845730-B2 1,3-substituted cyclobutyl derivatives and uses thereof CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2023-12-19 US disclosed
CN-117062804-A 1, 3-substituted cyclobutyl derivatives and their use 诺华股份有限公司 2023-11-14 CN disclosed
US-20220324811-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2022-10-13 US disclosed
WO-2022201097-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2022-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845730-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 IMPDH2 3733/4885GABRA1 283/4885GABRB2 218/4885
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 IMPDH2 3733/4885GABRA1 283/4885GABRB2 218/4885
US-20220324811-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF TRPV1, TRPV3, TRPV2 IMPDH2 3733/4885GABRA1 283/4885GABRB2 218/4885
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF TRPV1, TRPV3, TRPV2 IMPDH2 3733/4885GABRA1 283/4885GABRB2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.